Tilianin: A Potential Natural Lead Molecule for New Drug Design and Development for the Treatment of Cardiovascular Disorders
Cardiovascular disorders (CVDs) are the leading risk factor for death worldwide, and research into the processes and treatment regimens has received a lot of attention. Tilianin is a flavonoid glycoside that can be found in a wide range of medicinal plants and is most commonly obtained from <i>...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-01-01
|
| Series: | Molecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1420-3049/27/3/673 |
| _version_ | 1797486260116258816 |
|---|---|
| author | Farrah Syazana Khattulanuar Mahendran Sekar Shivkanya Fuloria Siew Hua Gan Nur Najihah Izzati Mat Rani Subban Ravi Kumarappan Chidambaram M. Yasmin Begum Abul Kalam Azad Srikanth Jeyabalan Arulmozhi Dhiravidamani Lakshmi Thangavelu Pei Teng Lum Vetriselvan Subramaniyan Yuan Seng Wu Kathiresan V. Sathasivam Neeraj Kumar Fuloria |
| author_facet | Farrah Syazana Khattulanuar Mahendran Sekar Shivkanya Fuloria Siew Hua Gan Nur Najihah Izzati Mat Rani Subban Ravi Kumarappan Chidambaram M. Yasmin Begum Abul Kalam Azad Srikanth Jeyabalan Arulmozhi Dhiravidamani Lakshmi Thangavelu Pei Teng Lum Vetriselvan Subramaniyan Yuan Seng Wu Kathiresan V. Sathasivam Neeraj Kumar Fuloria |
| author_sort | Farrah Syazana Khattulanuar |
| collection | DOAJ |
| description | Cardiovascular disorders (CVDs) are the leading risk factor for death worldwide, and research into the processes and treatment regimens has received a lot of attention. Tilianin is a flavonoid glycoside that can be found in a wide range of medicinal plants and is most commonly obtained from <i>Dracocephalum moldavica</i>. Due to its extensive range of biological actions, it has become a well-known molecule in recent years. In particular, numerous studies have shown that tilianin has cardioprotective properties against CVDs. Hence, this review summarises tilianin’s preclinical research in CVDs, as well as its mechanism of action and opportunities in future drug development. The physicochemical and drug-likeness properties, as well as the toxicity profile, were also highlighted. Tilianin can be a natural lead molecule in the therapy of CVDs such as coronary heart disease, angina pectoris, hypertension, and myocardial ischemia, according to scientific evidence. Free radical scavenging, inflammation control, mitochondrial function regulation, and related signalling pathways are all thought to play a role in tilianin’s cardioprotective actions. Finally, we discuss tilianin-derived compounds, as well as the limitations and opportunities of using tilianin as a lead molecule in drug development for CVDs. Overall, the scientific evidence presented in this review supports that tilianin and its derivatives could be used as a lead molecule in CVD drug development initiatives. |
| first_indexed | 2024-03-09T23:30:43Z |
| format | Article |
| id | doaj.art-e700aead579847079737847f40497371 |
| institution | Directory Open Access Journal |
| issn | 1420-3049 |
| language | English |
| last_indexed | 2024-03-09T23:30:43Z |
| publishDate | 2022-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Molecules |
| spelling | doaj.art-e700aead579847079737847f404973712023-11-23T17:10:33ZengMDPI AGMolecules1420-30492022-01-0127367310.3390/molecules27030673Tilianin: A Potential Natural Lead Molecule for New Drug Design and Development for the Treatment of Cardiovascular DisordersFarrah Syazana Khattulanuar0Mahendran Sekar1Shivkanya Fuloria2Siew Hua Gan3Nur Najihah Izzati Mat Rani4Subban Ravi5Kumarappan Chidambaram6M. Yasmin Begum7Abul Kalam Azad8Srikanth Jeyabalan9Arulmozhi Dhiravidamani10Lakshmi Thangavelu11Pei Teng Lum12Vetriselvan Subramaniyan13Yuan Seng Wu14Kathiresan V. Sathasivam15Neeraj Kumar Fuloria16Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Health Sciences, Royal College of Medicine Perak, Universiti Kuala Lumpur, Ipoh 30450, Perak, MalaysiaDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy and Health Sciences, Royal College of Medicine Perak, Universiti Kuala Lumpur, Ipoh 30450, Perak, MalaysiaFaculty of Pharmacy, AIMST University, Bedong, Kedah 08100, MalaysiaSchool of Pharmacy, Monash University Malaysia, Bandar Sunway, Selangor 47500, MalaysiaFaculty of Pharmacy and Health Sciences, Royal College of Medicine Perak, Universiti Kuala Lumpur, Ipoh 30450, Perak, MalaysiaDepartment of Chemistry, Karpagam Academy of Higher Education, Coimbatore 641021, Tamil Nadu, IndiaDepartment of Pharmacology, College of Pharmacy, King Khalid University, Abha 62529, Saudi ArabiaDepartment of Pharmaceutics, College of Pharmacy, King Khalid University, Abha 61421, Saudi ArabiaFaculty of Pharmacy, AIMST University, Bedong, Kedah 08100, MalaysiaDepartment of Pharmacology, Sri Ramachandra Faculty of Pharmacy, Sri Ramachandra Institute of Higher Education and Research (DU), Porur, Chennai 600116, Tamil Nadu, IndiaDepartment of Pharmacology, Sri Ramachandra Faculty of Pharmacy, Sri Ramachandra Institute of Higher Education and Research (DU), Porur, Chennai 600116, Tamil Nadu, IndiaCenter for Transdisciplinary Research, Department of Pharmacology, Saveetha Dental College and Hospital, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai 600077, IndiaDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy and Health Sciences, Royal College of Medicine Perak, Universiti Kuala Lumpur, Ipoh 30450, Perak, MalaysiaFaculty of Medicine, Bioscience and Nursing, MAHSA University, Jalan SP 2, Bandar Saujana Putra, Jenjarom 42610, Selangor, MalaysiaCentre for Virus and Vaccine Research, School of Medical and Life Sciences, Sunway University, Subang Jaya 47500, MalaysiaFaculty of Applied Sciences, AIMST University, Bedong, Kedah 08100, MalaysiaFaculty of Pharmacy, AIMST University, Bedong, Kedah 08100, MalaysiaCardiovascular disorders (CVDs) are the leading risk factor for death worldwide, and research into the processes and treatment regimens has received a lot of attention. Tilianin is a flavonoid glycoside that can be found in a wide range of medicinal plants and is most commonly obtained from <i>Dracocephalum moldavica</i>. Due to its extensive range of biological actions, it has become a well-known molecule in recent years. In particular, numerous studies have shown that tilianin has cardioprotective properties against CVDs. Hence, this review summarises tilianin’s preclinical research in CVDs, as well as its mechanism of action and opportunities in future drug development. The physicochemical and drug-likeness properties, as well as the toxicity profile, were also highlighted. Tilianin can be a natural lead molecule in the therapy of CVDs such as coronary heart disease, angina pectoris, hypertension, and myocardial ischemia, according to scientific evidence. Free radical scavenging, inflammation control, mitochondrial function regulation, and related signalling pathways are all thought to play a role in tilianin’s cardioprotective actions. Finally, we discuss tilianin-derived compounds, as well as the limitations and opportunities of using tilianin as a lead molecule in drug development for CVDs. Overall, the scientific evidence presented in this review supports that tilianin and its derivatives could be used as a lead molecule in CVD drug development initiatives.https://www.mdpi.com/1420-3049/27/3/673tilianincardiovascular disorderscardioprotectionmolecular mechanismdrug-likenessdrug development |
| spellingShingle | Farrah Syazana Khattulanuar Mahendran Sekar Shivkanya Fuloria Siew Hua Gan Nur Najihah Izzati Mat Rani Subban Ravi Kumarappan Chidambaram M. Yasmin Begum Abul Kalam Azad Srikanth Jeyabalan Arulmozhi Dhiravidamani Lakshmi Thangavelu Pei Teng Lum Vetriselvan Subramaniyan Yuan Seng Wu Kathiresan V. Sathasivam Neeraj Kumar Fuloria Tilianin: A Potential Natural Lead Molecule for New Drug Design and Development for the Treatment of Cardiovascular Disorders Molecules tilianin cardiovascular disorders cardioprotection molecular mechanism drug-likeness drug development |
| title | Tilianin: A Potential Natural Lead Molecule for New Drug Design and Development for the Treatment of Cardiovascular Disorders |
| title_full | Tilianin: A Potential Natural Lead Molecule for New Drug Design and Development for the Treatment of Cardiovascular Disorders |
| title_fullStr | Tilianin: A Potential Natural Lead Molecule for New Drug Design and Development for the Treatment of Cardiovascular Disorders |
| title_full_unstemmed | Tilianin: A Potential Natural Lead Molecule for New Drug Design and Development for the Treatment of Cardiovascular Disorders |
| title_short | Tilianin: A Potential Natural Lead Molecule for New Drug Design and Development for the Treatment of Cardiovascular Disorders |
| title_sort | tilianin a potential natural lead molecule for new drug design and development for the treatment of cardiovascular disorders |
| topic | tilianin cardiovascular disorders cardioprotection molecular mechanism drug-likeness drug development |
| url | https://www.mdpi.com/1420-3049/27/3/673 |
| work_keys_str_mv | AT farrahsyazanakhattulanuar tilianinapotentialnaturalleadmoleculefornewdrugdesignanddevelopmentforthetreatmentofcardiovasculardisorders AT mahendransekar tilianinapotentialnaturalleadmoleculefornewdrugdesignanddevelopmentforthetreatmentofcardiovasculardisorders AT shivkanyafuloria tilianinapotentialnaturalleadmoleculefornewdrugdesignanddevelopmentforthetreatmentofcardiovasculardisorders AT siewhuagan tilianinapotentialnaturalleadmoleculefornewdrugdesignanddevelopmentforthetreatmentofcardiovasculardisorders AT nurnajihahizzatimatrani tilianinapotentialnaturalleadmoleculefornewdrugdesignanddevelopmentforthetreatmentofcardiovasculardisorders AT subbanravi tilianinapotentialnaturalleadmoleculefornewdrugdesignanddevelopmentforthetreatmentofcardiovasculardisorders AT kumarappanchidambaram tilianinapotentialnaturalleadmoleculefornewdrugdesignanddevelopmentforthetreatmentofcardiovasculardisorders AT myasminbegum tilianinapotentialnaturalleadmoleculefornewdrugdesignanddevelopmentforthetreatmentofcardiovasculardisorders AT abulkalamazad tilianinapotentialnaturalleadmoleculefornewdrugdesignanddevelopmentforthetreatmentofcardiovasculardisorders AT srikanthjeyabalan tilianinapotentialnaturalleadmoleculefornewdrugdesignanddevelopmentforthetreatmentofcardiovasculardisorders AT arulmozhidhiravidamani tilianinapotentialnaturalleadmoleculefornewdrugdesignanddevelopmentforthetreatmentofcardiovasculardisorders AT lakshmithangavelu tilianinapotentialnaturalleadmoleculefornewdrugdesignanddevelopmentforthetreatmentofcardiovasculardisorders AT peitenglum tilianinapotentialnaturalleadmoleculefornewdrugdesignanddevelopmentforthetreatmentofcardiovasculardisorders AT vetriselvansubramaniyan tilianinapotentialnaturalleadmoleculefornewdrugdesignanddevelopmentforthetreatmentofcardiovasculardisorders AT yuansengwu tilianinapotentialnaturalleadmoleculefornewdrugdesignanddevelopmentforthetreatmentofcardiovasculardisorders AT kathiresanvsathasivam tilianinapotentialnaturalleadmoleculefornewdrugdesignanddevelopmentforthetreatmentofcardiovasculardisorders AT neerajkumarfuloria tilianinapotentialnaturalleadmoleculefornewdrugdesignanddevelopmentforthetreatmentofcardiovasculardisorders |